Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorBoston Children's Hospital

About this trial

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a condition with several causes of which some remain unknown. It is believed that some types of CP may be genetic or passed down (inherited) from one generation to the next.

In this study, we are collecting genetic material and medical information to try to determine if genetic factors play a role in CP/CPPS. We will be collecting DNA (from Blood/Saliva sample) and urine from each participant. Bladder tissue from affected individuals will also be collected. Individuals and families with CP/CPPS will be enrolled. Family members of an individual with CP/CPPS are eligible whether or not they also experience CP/CPPS symptoms.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pain in the pelvic area

Urinary frequency and/or

Urinary urgency and/or

Sexual dysfunction (erectile dysfunction)

Disqualifiers

Major structural/anatomical urinary tract abnormalities

Underlying inborn or congenital conditions which affect the urinary tract

Surgery/chemotherapy in the pelvic area

Bacterial cause to CP/CPPS or recurrent Urinary tract infections (UTI)

Trial population

We are collecting individuals with a diagnoses of CP/CPPS and their family members (with or without symptoms) from North America (United States and Canada). Preference is given to families with multiple affected individuals (males or females with IC/BPS/CPPS).

Trial design

Design model

Family-based

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Participants With Candidate Disease-Causing Genetic Variant(s) Associated With CP/CPPS or IC/BPS

DNA from blood/saliva and, when available, bladder or skin tissue will be analyzed using linkage analysis, whole exome/genome sequencing, and candidate gene approaches to identify candidate disease-causing variants associated with CP/CPPS, IC/BPS, PBS, or BFS. The measure will be summarized as the number of participants with candidate disease-causing variant(s), and when applicable, co-segregation of variants with affected status or symptoms.

Time frame
From enrollment until completion of genetic analysis for the participant or family, up to 22 years.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.